title: [Psoriasis-like eruption induced by adalimumab in a patient with rheumatoid arthritis : a case report and review of literature].
abstract: A 72-year-old man developed arthritis of the bilateral shoulders and fingers. X-ray examination of the fingers showed periarticular osteoporosis, joint space narrowing, and cystic changes at the bone ends. Because contrast-enhanced MRI revealed synovial membrane proliferation and osteolysis, a diagnosis of rheumatoid arthritis (RA) was made. Treatment for RA with methotrexate (4 mg/week) was initiated in December 2008. In February 2009, adalimumab administration (40 mg/2 weeks) was initiated. The RA markedly improved, and clinical remission was maintained thereafter. However, in April 2010, relatively well-delineated erythematous plaques accompanied by bullae and scales developed on the bilateral palms, toes, limbs, and the inguinal region. A diagnosis of psoriasis-like eruptions was made by skin biopsy, and adalimumab administration was discontinued. After 4 months, the eruptions improved. Psoriasis-like eruptions due to anti-TNF drugs are rarely observed, but adverse effects require caution. This case is reported along with a review of the literature.
authors.affiliation: Department of Internal Medicine I, Osaka Medical College, Takatsuki, Osaka.
authors.forename: Haruna
authors.initials: H
authors.lastname: Kuno
authors.forename: Takuya
authors.initials: T
authors.lastname: Kotani
authors.forename: Tohru
authors.initials: T
authors.lastname: Takeuchi
authors.forename: Daisuke
authors.initials: D
authors.lastname: Wakura
authors.forename: Reiko
authors.initials: R
authors.lastname: Wakura
authors.forename: Akitoshi
authors.initials: A
authors.lastname: Yu
authors.forename: Shigeki
authors.initials: S
authors.lastname: Makino
authors.forename: Shinichi
authors.initials: S
authors.lastname: Moriwaki
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Hanafusa
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003875:Drug Eruptions / Q000209:etiology*; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab